TP53 and neoplasm: Certainly, when mouse models with activating KRAS mutations are combined with a loss-of-function TP53 and/or CDKN2A mutation, an acceleration of PDAC growth, more genetic instability and a tendency for poorly differentiated tumours is seen [20].